Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 24;9(1):13.
doi: 10.1186/s40170-021-00247-8.

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes

Sinthu Pathmanapan  1   2 , Olga Ilkayeva  3   4 , John T Martin  5 , Adrian Kwan Ho Loe  1 , Hongyuan Zhang  5 , Guo-Fang Zhang  4 , Christopher B Newgard  3   4 , Jay S Wunder  6 , Benjamin A Alman  7
Affiliations

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes

Sinthu Pathmanapan et al. Cancer Metab. .

Abstract

Background: Majority of chondrosarcomas are associated with a number of genetic alterations, including somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, but the downstream effects of these mutated enzymes on cellular metabolism and tumor energetics are unknown. As IDH mutations are likely to be involved in malignant transformation of chondrosarcomas, we aimed to exploit metabolomic changes in IDH mutant and non-mutant chondrosarcomas.

Methods: Here, we profiled over 69 metabolites in 17 patient-derived xenografts by targeted mass spectrometry to determine if metabolomic differences exist in mutant IDH1, mutant IDH2, and non-mutant chondrosarcomas. UMAP (Uniform Manifold Approximation and Projection) analysis was performed on our dataset to examine potential similarities that may exist between each chondrosarcoma based on genotype.

Results: UMAP revealed that mutant IDH chondrosarcomas possess a distinct metabolic profile compared with non-mutant chondrosarcomas. More specifically, our targeted metabolomics study revealed large-scale differences in organic acid intermediates of the tricarboxylic acid (TCA) cycle, amino acids, and specific acylcarnitines in chondrosarcomas. Lactate and late TCA cycle intermediates were elevated in mutant IDH chondrosarcomas, suggestive of increased glycolytic metabolism and possible anaplerotic influx to the TCA cycle. A broad elevation of amino acids was found in mutant IDH chondrosarcomas. A few acylcarnitines of varying carbon chain lengths were also elevated in mutant IDH chondrosarcomas, but with minimal clustering in accordance with tumor genotype. Analysis of previously published gene expression profiling revealed increased expression of several metabolism genes in mutant IDH chondrosarcomas, which also correlated to patient survival.

Conclusions: Overall, our findings suggest that IDH mutations induce global metabolic changes in chondrosarcomas and shed light on deranged metabolic pathways.

Keywords: Acylcarnitines; Amino acids; Cancer; Chondrosarcoma; Genetic mutation; Glycolysis; Metabolism; Mutant IDH; TCA cycle.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Organic acid quantification of non-mutant, mutant IDH1, and mutant IDH2 chondrosarcoma tissue by gas chromatography/mass spectrometry (GC/MS). Quantification of glycolytic a pyruvate, b lactate and TCA cycle metabolites c citrate, d ⍺-ketoglutarate, e succinate, f fumarate, g malate, of non-mutant, mutant IDH1, and mutant IDH2 chondrosarcoma tissue. p-value = Student’s t-test p < 0.05, *: significant p-value
Fig. 2
Fig. 2
Amino acid profiles of non-mutant, mutant IDH, and mutant IDH2 chondrosarcoma tissue quantified by mass spectrometry (MS/MS) display a global elevation in mutant IDH chondrosarcomas. Radar profiles of a non-mutant chondrosarcomas, b mutant IDH1 chondrosarcomas, c mutant IDH2 chondrosarcomas, d scatter plot of amino acids in each genotype of chondrosarcoma. p-value = Student’s t-test p < 0.05, *: significant p-value
Fig. 3
Fig. 3
Acylcarnitine profiles of non-mutant, mutant IDH1, and mutant IDH2 chondrosarcoma tissues, quantified by mass spectrometry (MS/MS) display an elevation of species in mutant IDH chondrosarcomas. Acylcarnitines classified according to increasing carbon chain length: a short-chain acylcarnitines, b medium-chain acylcarnitines, c long-chain acylcarnitines, d very-long-chain acylcarnitines. p-value = Student’s t-test p < 0.05, *: significant p-value
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Hirata M, Sasaki M, Cairns RA, Inoue S, Puviindran V, Li WY, Snow BE, Jones LD, Wei Q, Sato S, Tang YJ, Nadesan P, Rockel J, Whetstone H, Poon R, Weng A, Gross S, Straley K, Gliser C, Xu Y, Wunder J, Mak TW, Alman BA. Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci. 2015;112(9):2829–2834. doi: 10.1073/pnas.1424400112. - DOI - PMC - PubMed
    1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PCW, Futreal A, Tirabosco R, Flanagan AM. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–343. doi: 10.1002/path.2913. - DOI - PubMed
    1. Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. Br J Cancer. 2018;118(8):1074–1083. doi: 10.1038/s41416-018-0050-9. - DOI - PMC - PubMed
    1. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: New insights and promises for the future. JAMA Neurol. 2014;71(10):1319–1325. doi: 10.1001/jamaneurol.2014.1205. - DOI - PubMed